Apex Labs Expands Macrodose Psilocybin PTSD Trial
Apex Labs Ltd. received approval from Israel’s Ministry of Health to expand its phase 2b clinical trial, SUMMIT-90, for...
Neurostimulation Trial for Opioid Disorder Shows Promising Results
Spark Biomedical concluded enrollment for its pivotal clinical trial using transcutaneous auricular neurostimulation (tAN) to improve treatment retention for...
One Medicine, One Platform: How Boehringer Ingelheim Is Redefining Pharma Transformation
At the 2025 Veeva R&D and Quality Summit Europe, Martin Helling, Executive Director of the One Medicine Platform at...
AI’s Transformative Role in Clinical Trials: Insights from Lokavant’s CEO
Artificial intelligence (AI) is reshaping clinical trials, offering new efficiencies and insights. Rohit Nambisan, CEO of Lokavant, shares his...
Atai & Beckley Psychedelic Merger Creates Global Mental Health Leader
Atai Life Sciences and Beckley Psytech are merging in an all-stock transaction, creating atai Beckley, a leading mental health...
Promising Data: Alrizomadlin in Solid Tumors
Ascentage Pharma released Phase II clinical trial data for its MDM2-p53 inhibitor, alrizomadlin (APG-115), at the 2025 ASCO Annual...
RECELL Reduced Hospital Stays: Largest Real-World Analysis
AVITA Medical highlighted data from the British Burn Association Annual Meeting showing that RECELL, its spray-on skin cell technology,...
Polypid’s Shield II Phase 3 Trial Delivers Groundbreaking Results
PolyPid Ltd. announced positive topline results from its Phase 3 SHIELD II trial of D-PLEX100 for preventing surgical site...
Humacyte’s AV Access Study Shows Promising Results
Humacyte, a biotech company focused on bioengineered human tissues, presented positive Phase 3 clinical trial results for their acellular...
Metsera Announces Positive Phase 1 Data of Amylin Candidate
Metsera, Inc. announced positive Phase 1 clinical trial data for MET-233i, a new ultra-long-acting amylin analog designed for monthly...